Which patients with Crohn disease are most likely to benefit from tumor necrosis factor (TNF) therapy?

Updated: Jul 26, 2019
  • Author: Leyla J Ghazi, MD; Chief Editor: Praveen K Roy, MD, AGAF  more...
  • Print

Tumor necrosis factor (TNF), a key inflammatory cytokine and mediator of intestinal inflammation, is expressed prominently in inflammatory bowel disease (IBD). Patients likely to benefit from anti-TNF therapy include the following [84] :

  • Patients who have moderate to severe debilitating symptoms of Crohn disease, who have documented active inflammation, or who are dependent on corticosteroids and unable to taper these agents without return of symptoms

  • Patients who do not show evidence of active bowel infection as a cause of GI symptoms

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!